(Q43415543)

23 November 2017

Genetic variants associated with predisposition to prostate cancer and potential clinical implications (English)

1 reference

23 November 2017

1 reference

7

1 reference

23 November 2017

3

D Easton

1 reference

23 November 2017

4

K Muir

1 reference

23 November 2017

6

Z Kote-Jarai

1 reference

23 November 2017

5

B Henderson

1 reference

23 November 2017

C L Goh

1

1 reference

PubMed ID

22308973

23 November 2017

F R Schumacher

series ordinal

2

1 reference

PubMed ID

22308973

23 November 2017

language of work or name

English

0 references

publication date

1 April 2012

1 reference

Journal of Internal Medicine

23 November 2017

1 reference

23 November 2017

271

1 reference

23 November 2017

4

1 reference

23 November 2017

353-365

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

23 November 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Global patterns of cancer incidence and mortality rates and trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Epidemiology of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Spatial patterns of localized-stage prostate cancer incidence among white and black men in the southeastern United States, 1999-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The complex genetic epidemiology of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Early detection of prostate cancer with emphasis on genetic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association studies in cancer--current and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Multiple loci on 8q24 associated with prostate cancer susceptibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A common variant associated with prostate cancer in European and African populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Multiple newly identified loci associated with prostate cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study identifies new prostate cancer susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Multiple loci identified in a genome-wide association study of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Unravelling the genetics of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Mendelian inheritance of familial prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Transmission disequilibrium, family controls, and great expectations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Rapid progression of prostate cancer in men with a BRCA2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Rare germline mutations in the BRCA2 gene are associated with early-onset prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A novel founder CHEK2 mutation is associated with increased prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A large germline deletion in the Chek2 kinase gene is associated with an increased risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A recurrent mutation in PALB2 in Finnish cancer families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Normal tissue reactions to radiotherapy: towards tailoring treatment dose by genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Ancestry and disease in the age of genomic medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association studies in common cancers--what have we learnt?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Mutation analysis of the MSMB gene in familial prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Multiple novel prostate cancer predisposition loci confirmed by an international study: the PRACTICAL Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The interaction of four genes in the inflammation pathway significantly predicts prostate cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

C-reactive protein haplotype is associated with high PSA as a marker of metastatic prostate cancer but not with overall cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Principles for the post-GWAS functional characterization of cancer risk loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Active surveillance for low-risk prostate cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

External-beam radiotherapy for localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genetic variants and normal tissue toxicity after radiotherapy: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genetic variation in normal tissue toxicity induced by ionizing radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Establishment of a Radiogenomics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Androgen receptor polymorphisms and risk of biochemical failure among prostatectomy patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Pathological aggressiveness of prostatic carcinomas related to RNASEL R462Q allelic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The matrix metalloproteinase-7 polymorphism rs10895304 is associated with increased recurrence risk in patients with clinically localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Toll-like receptor signaling pathway variants and prostate cancer mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate cancer risk allele specific for African descent associates with pathologic stage at prostatectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Endocrine therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Gonadotropin-releasing hormone agonists in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Endocrine therapy for prostate cancer: recent developments and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Androgen deprivation therapy for prostate cancer: new concepts and concerns

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Molecular Cloning of Human and Rat Complementary DNA Encoding Androgen Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genetic alterations of androgen receptor gene in Japanese human prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Screening of genetic and expression alterations of SRC1 gene in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Association of megalin genetic polymorphisms with prostate cancer risk and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Estimation of absolute risk for prostate cancer using genetic markers and family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Nomograms for staging, prognosis, and predicting treatment outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

What is low-risk prostate cancer and what is its natural history?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Effect of genetic variability within 8q24 on aggressiveness patterns at diagnosis and familial status of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Association of prostate cancer risk variants with clinicopathologic characteristics of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate cancer susceptibility variants confer increased risk of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate cancer risk variants are not associated with disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Clinical utility of five genetic variants for predicting prostate cancer risk and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

A practical guide to prostate cancer diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Mortality results from a randomized prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Mortality results from the Göteborg randomised population-based prostate-cancer screening trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Utility of incorporating genetic variants for the early detection of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Polygenic susceptibility to prostate and breast cancer: implications for personalised screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Diet, anthropometric measures and prostate cancer risk: a review of prospective cohort and intervention studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Diet, lifestyle and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Dairy products, calcium, and vitamin D and risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Fat, meat, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Tomatoes, tomato-based products, lycopene, and cancer: review of the epidemiologic literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Association between plasma cholesterol and prostate cancer in the PSA era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Statin drugs and risk of advanced prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Effect of dutasteride on the risk of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The influence of finasteride on the development of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Chemoprevention of Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Two variants on chromosome 17 confer prostate cancer risk and the one in TCF2 protects against type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate Testing for Cancer and Treatment (ProtecT) feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

Prostate Cancer Progression and Survival in BRCA2 Mutation Carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2012.02511.X

10.1111/J.1365-2796.2012.02511.X

21 January 2018

Identifiers

DOI

1 reference

23 November 2017

1 reference

PubMed ID

22308973